AbCellera Biologics Inc (ABCL)
2.715
-0.16
(-5.73%)
USD |
NASDAQ |
Nov 05, 16:00
2.715
0.00 (0.00%)
After-Hours: 19:17
AbCellera Biologics Revenue (Quarterly): 7.323M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 7.323M |
| March 31, 2024 | 9.954M |
| December 31, 2023 | 9.179M |
| September 30, 2023 | 6.599M |
| June 30, 2023 | 10.06M |
| March 31, 2023 | 12.19M |
| December 31, 2022 | 21.54M |
| September 30, 2022 | 101.38M |
| June 30, 2022 | 45.92M |
| March 31, 2022 | 316.58M |
| Date | Value |
|---|---|
| December 31, 2021 | 139.33M |
| September 30, 2021 | 5.508M |
| June 30, 2021 | 27.64M |
| March 31, 2021 | 202.74M |
| December 31, 2020 | 207.91M |
| September 30, 2020 | 9.362M |
| June 30, 2020 | 11.23M |
| March 31, 2020 | 4.657M |
| December 31, 2019 | 3.203M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
3.203M
Minimum
Dec 2019
316.58M
Maximum
Mar 2022
60.65M
Average
11.23M
Median
Jun 2020
Revenue (Quarterly) Benchmarks
| Grace Therapeutics Inc | -- |
| Aurinia Pharmaceuticals Inc | 57.19M |
| Edesa Biotech Inc | -- |
| Lexaria Bioscience Corp | 0.084M |
| InMed Pharmaceuticals Inc | 1.283M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -36.93M |
| Total Expenses (Quarterly) | 97.47M |
| EPS Diluted (Quarterly) | -0.13 |
| Enterprise Value | 178.28M |
| Profit Margin (Quarterly) | -504.3% |
| Earnings Yield | -19.89% |
| Normalized Earnings Yield | -19.89 |